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 Current wound management for chronic diabetic ulcers is unreliable and frequently 
fails. Due to this unsatisfactory outcome, many diabetic patients are at risk for further 
complications such as amputations or death. Hyperbaric oxygen therapy (HBOT) has the 
potential to promote chronic diabetic ulcer healing as an adjunct treatment tool by reducing 
tissue hypoxia and ischemia. The purpose of this medical literature review is to examine the 
effect of HBOT, compared to standard wound care alone, on chronic diabetic lower extremity 
ulcer healing. Unfortunately, limitations of existing medical evidence hinder the use of HBOT as 
a conventional treatment modality for non-healing diabetic wounds. Further discussion involves 
diabetic lower extremity ulcer etiology, normal wound healing physiology, chronic wound 
physiology in diabetic patients, and present HBOT research.  
INTRODUCTION 
Chronic lower extremity ulcers are a common complication seen in diabetic patients. 
Currently there is no defined treatment regimen used to heal chronic diabetic wounds 
effectively and to ultimately decrease the associated costs and risks involved. In the United 
States, it is estimated that 15% of diabetic patients develop foot ulcers, and 14-24% of those 
patients will require an amputation.1 The average cost of healing a single non-infected ulcer is 
$8,000, and the average cost for a major amputation is $45,000. In addition, about 50% of 
people with amputations will develop ulcers in the opposite limb within 18 months, and the 
three-year mortality after one amputation is estimated to be 20-50%.2 Due to these facts, there 
is debate whether hyperbaric oxygen therapy (HBOT) can play an effective role as an adjunct 




Wound management has evolved substantially over the years to promote healing in 
different types of cutaneous injuries through various treatment regimens. However, there are 
several situations that make the wound healing process a grueling challenge. These conditions 
include extensive burns, ischemia, venous or arterial insufficiency, immune compromise, and 
pressure areas.9 One of the most common diseases that yields complication in the wound 
healing process, eventually leading to chronic wound status, is diabetes.3 Non-healing lower 
extremity ulcers are a prevalent complication among the diabetic population, potentially 
leading to a decline in quality of life, and even amputation and death.4 The chronic ulcers 
frequently arise from complications of diabetic neuropathy, peripheral vascular disease, edema, 
calluses, or trauma. The wounds require extensive treatment practices such as tissue 
debridement, infection control, and pressure relief. However, many of the treatments leave 
these patients with poor results.2-4  
A chronic diabetic ulcer is described to be any lower extremity wound that has been 
present for over one month and where attempts to heal by standard wound care methods have 
failed. Standard wound care is considered to be any localized treatment, such as topical 
ointments or solutions, dressings, or tissue debridement.8,9 One possible solution to treating 
non-healing diabetic ulcers is the addition of HBOT to current treatment regimens. HBOT is the 
administration of 100% oxygen exposure at a high pressure, generally around 2-3 atmosphere 
absolute (ata) pressure, for several minutes once or twice daily. It is performed by placing the 
patient’s body in a pressurized chamber and allowing them to breathe the concentrated oxygen 
in order to increase the availability for body tissues. The role of HBOT as a modality for chronic 




sessions; therefore, stimulating and continuing the healing process.6-8 Although chronic diabetic 
ulcers involve hyperglycemia in addition to ischemia, HBOT may demonstrate benefit as 
supplementary care by acting on the ischemic portion of the chronic wounds. The purpose of 
this literature review is to examine the effect of HBOT, compared to standard wound care 
alone, on wound healing in chronic diabetic lower extremity ulcers, up to one year after 
treatment. It is important to identify new treatment regimens for chronic diabetic ulcers in 
order to improve quality of life and prevent further complications such as amputation.  
DISCUSSION 
 Normal wound healing consists of three confluent phases: inflammatory, proliferative, 
and tissue remodeling (Fig. 1).10 The inflammatory phase consists of vessel constriction and 
platelet aggregation. It begins immediately after the wound injury occurs and continues for four 
to six days. Next, the proliferative phase involves granulation, blood vessel formation, and re-
epithelization. This process can take a few weeks to complete. Finally, the tissue remodeling 
phase concludes the entire process via wound contraction and fibroblast activation, which 
ultimately leads to wound closure. This phase can take up to a couple years. The first two 
stages utilize acute hypoxia and reactive oxygen species (ROS) activity to begin and promote 
the healing process, while oxygen recovery in the third phase enables completion of the 
process. Throughout the healing series, vascular endothelin growth factor (VEGF) plays an 
important role for the development and maintenance of blood vessels, endothelin-1 is 
necessary for vasoconstriction to essentially maintain vascular tone, and interleukin 6 (IL-6) has 






Excerpted from Schreml S, Szeimies RM, Prantl L, Karrer S, Landthaler M, Babilas P. Oxygen in 
acute and chronic wound healing. Br J Dermatol. 2010;163(2):257-268. doi:10.1111/j.1365-
2133.2010.09804.x 
 
Fig 1. Normal physiologic phases of the wound healing process and corresponding activity 
response over time. Chronic wound physiology is also represented by continuation of the 
inflammatory phase.10 
In chronic wounds, such as lower extremity diabetic ulcers, the normal events of wound 
healing are not accomplished. Many factors not only contribute to the etiology, they play a role 
in the prevention of wound closure as well. Some of these causes include tissue hypoxia, 
bacterial overgrowth, and ischemia. Due to these issues, chronic wounds remain in the 
inflammatory phase and cannot progress to full tissue healing (Fig. 1).10 This is also true for 
chronic diabetic ulcers. With the persistence of tissue hypoxia, vascular insufficiency, immune 
incompetence and hyperglycemia, many diabetic ulcers remain in the first phase of the healing 
process and thus become chronic. The continuation of the ulcers can then lead to further 
complications that greatly affect quality of life (e.g. disability or amputation), or even threaten 




HBOT is considered to be an adjunct treatment modality to promote diabetic ulcer 
healing by ending the ongoing hypoxic and ischemic state of the chronic wounds. This idea is 
demonstrated in a study conducted on rats, which investigates the role of HBOT in ischemic 
and/or hyperglycemic wound states. It was found that the ischemic and hyperglycemic wounds 
that underwent HBOT (experimental groups) had decreased wound size and less closure time 
when compared to the control groups. However, there was no significant difference found in 
wound contraction and re-epithelialization between the groups. In addition, ischemic wounds 
in hyperglycemic conditions benefited the most from HBOT.12 Based on these results, HBOT 
may possess the potential to promote ulcer healing in diabetic patients.  
In data collected from 971 diabetic patients that underwent HBOT, it was found that 
wounds with a modified Wagner grading of 3 or higher showed the most benefit from HBOT. It 
was also found that the greatest wound healing appeared within the first fifteen treatments. 
Amputation rates were seen to be doubled in patients with interrupted treatments as opposed 
to those with uninterrupted therapy sessions.6 This suggests that patients with more extensive 
ulcers may benefit most from HBOT, as opposed to less severe wounds. Nevertheless, the study 
was retrospective and did not incorporate a control group.  
Additionally, HBOT was found to significantly impact VEGF, enothelin-1 and IL-6 plasma 
levels. In a study that examined chronic wounds and their responses to HBOT, it was found that 
VEGF and IL-6 levels significantly increased after each treatment session, whereas endothelin-1 
progressively decreased over the sessions. These level changes promoted angiogenesis, 
regulation of vascular tone, and decreased inflammation in the wounds, ultimately leading to 




potential to break out of a prolonged inflammatory phase, and progress through the remaining 
stages of the healing process. Unfortunately, the study included a small sample size and various 
chronic wound etiologies, as opposed to focusing primarily on diabetic ulcers.  
Although HBOT is considered safe at common treatment pressures, there are still risks 
involved. Complications are categorized as either pressure- or oxygen-related. These include 
middle ear barotrauma, sinus squeeze, pulmonary barotrauma, seizures, myopia, 
claustrophobia, and pulmonary-related oxygen toxicity. The most frequent adverse event 
experienced during treatment is middle ear barotrauma, which is also the most common 
reason for termination of HOBT. Nevertheless, the majority of complications are benign and 
treatable. To decrease the risk, it is recommended that patients be evaluated before, during, 
and after each session. It is also important that operational protocols are set and followed for 
each session. When these precautions are followed, HBOT is considered a safe treatment 
modality.7,13 
CONCLUSION 
 The effect of HBOT on chronic diabetic lower extremity ulcer healing appears to be 
more beneficial than standard wound care alone. Based on current studies, adding HBOT to 
treatment regimens may promote complete chronic wound healing, and at a quicker rate. This 
response is due to the influence of HBOT on tissue oxygenation and stimulation of the proper 
wound healing cycle. Ultimately, HBOT may end the persistence of chronic diabetic ulcers, and 
thus decrease the necessity for amputations and the risk of developing other complications.  
 Although HBOT has the potential to positively impact chronic diabetic wounds, more 




research has demonstrated the beneficial effect of HBOT; however, many of the supporting 
studies include small sample sizes, numerous chronic wound etiologies, experimentation on 
animals, various treatment protocols, etc. In order to make a strong recommendation for the 
use of HBOT in diabetic patients with chronic lower extremity ulcers, more research must be 
performed on larger numbers of patients with diabetic wounds, and specific treatment 
protocols need to be established. It is also important to determine the cost effectiveness of 
HBOT and establish which types of chronic diabetic ulcers will benefit most from the therapy. In 
conclusion, current therapies for chronic diabetic wounds regularly have poor outcomes; 
therefore, it is essential to find new treatment regimens. HBOT may prove to be a promising 
adjunct modality to standard wound care, and if this is the case, it can positively impact the 
quality of life and mortality rates in diabetic patients. 
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